| Year |
Citation |
Score |
| 2023 |
Tantawy SI, Timofeeva N, Sarkar A, Gandhi V. Targeting MCL-1 protein to treat cancer: opportunities and challenges. Frontiers in Oncology. 13: 1226289. PMID 37601693 DOI: 10.3389/fonc.2023.1226289 |
0.304 |
|
| 2023 |
Timofeeva N, Ayres ML, Baran N, Santiago-O'Farrill JM, Bildik G, Lu Z, Konopleva M, Gandhi V. Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia. Frontiers in Oncology. 13: 1161254. PMID 37228498 DOI: 10.3389/fonc.2023.1161254 |
0.336 |
|
| 2022 |
Aslan B, Kismali G, Iles LR, Manyam GC, Ayres ML, Chen LS, Gagea M, Bertilaccio MTS, Wierda WG, Gandhi V. Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. Blood Cancer Journal. 12: 80. PMID 35595730 DOI: 10.1038/s41408-022-00675-9 |
0.34 |
|
| 2022 |
Yi X, Jain N, Iles LR, Ayres ML, Wierda WG, Gandhi V. Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia. Frontiers in Oncology. 12: 833714. PMID 35273915 DOI: 10.3389/fonc.2022.833714 |
0.368 |
|
| 2021 |
Galan-Cobo A, Stellrecht CM, Yilmaz E, Yang C, Qian Y, Qu X, Akhter I, Ayres ML, Fan Y, Tong P, Diao L, Ding J, Giri U, Gudikote J, Nilsson M, ... ... Gandhi V, et al. Enhanced vulnerability of LKB1-deficient NSCLC to disruption of ATP pools and redox homeostasis by 8-Cl-Ado. Molecular Cancer Research : McR. PMID 34654720 DOI: 10.1158/1541-7786.MCR-21-0448 |
0.31 |
|
| 2021 |
Aslan B, Kismali G, Chen LS, Iles LR, Mahendra M, Peoples M, Gagea M, Fowlkes NW, Zheng X, Wang J, Vellano CP, Marszalek JR, Bertilaccio MTS, Gandhi V. Development and characterization of prototypes for in vitro and in vivo mouse models of ibrutinib-resistant CLL. Blood Advances. 5: 3134-3146. PMID 34424317 DOI: 10.1182/bloodadvances.2020003821 |
0.323 |
|
| 2021 |
Timofeeva N, Gandhi V. Ibrutinib combinations in CLL therapy: scientific rationale and clinical results. Blood Cancer Journal. 11: 79. PMID 33927183 DOI: 10.1038/s41408-021-00467-7 |
0.359 |
|
| 2021 |
Buettner R, Nguyen LXT, Morales C, Chen MH, Wu X, Chen LS, Hoang DH, Hernandez Vargas S, Pullarkat V, Gandhi V, Marcucci G, Rosen ST. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine. Journal of Hematology & Oncology. 14: 70. PMID 33902674 DOI: 10.1186/s13045-021-01076-4 |
0.328 |
|
| 2021 |
Bose P, Gandhi V. Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors. Faculty Reviews. 10: 22. PMID 33718939 DOI: 10.12703/r/10-22 |
0.314 |
|
| 2020 |
Sarkar A, Stellrecht CM, Vangapandu HV, Ayres M, Kaipparettu BA, Park JH, Balakrishnan K, Burks JK, Pandita TK, Hittelman WN, Neelapu SS, Gandhi V. Ataxia telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma. Haematologica. PMID 32029507 DOI: 10.3324/Haematol.2019.234385 |
0.473 |
|
| 2020 |
Yi X, Sarkar A, Kismali G, Aslan B, Ayres M, Iles LR, Keating MJ, Wierda W, Long JP, Bertilaccio MTS, Gandhi V. AMG-176, an Mcl-1 antagonist, shows preclinical efficacy in chronic lymphocytic leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31937611 DOI: 10.1158/1078-0432.Ccr-19-1397 |
0.458 |
|
| 2019 |
Banerjee P, Zhang R, Ivan C, Galletti G, Clise-Dwyer K, Barbaglio F, Scarfò L, Aracil M, Klein C, Wierda W, Plunkett W, Caligaris Cappio F, Gandhi V, Keating MJ, Bertilaccio MTS. Trabectedin reveals a strategy of immunomodulation in chronic lymphocytic leukemia. Cancer Immunology Research. PMID 31530560 DOI: 10.1158/2326-6066.Cir-19-0152 |
0.377 |
|
| 2019 |
Chen LS, Keating MJ, Wierda WG, Gandhi V. Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells. Leukemia & Lymphoma. 1-4. PMID 31161836 DOI: 10.1080/10428194.2019.1622098 |
0.435 |
|
| 2019 |
Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, ... ... Gandhi V, et al. Ibrutinib and Venetoclax for First-Line Treatment of CLL. The New England Journal of Medicine. 380: 2095-2103. PMID 31141631 DOI: 10.1056/Nejmoa1900574 |
0.444 |
|
| 2019 |
Cervantes-Gomez F, Stellrecht CM, Ayres ML, Keating MJ, Wierda WG, Gandhi V. PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells. Oncotarget. 10: 2793-2809. PMID 31073371 DOI: 10.18632/Oncotarget.26876 |
0.512 |
|
| 2019 |
Galan-Cobo A, Sitthideatphaiboon P, Qu X, Poteete A, Pisegna MA, Tong P, Chen PH, Boroughs LK, Rodriguez MLM, Zhang W, Parlati F, Wang J, Gandhi V, Skoulidis F, DeBerardinis RJ, et al. LKB1 and KEAP1/NRF2 pathways cooperatively promote metabolic reprogramming with enhanced glutamine dependence in KRAS-mutant lung adenocarcinoma. Cancer Research. PMID 31040157 DOI: 10.1158/0008-5472.Can-18-3527 |
0.342 |
|
| 2019 |
Buettner R, Nguyen LXT, Kumar B, Morales C, Liu C, Chen LS, Pemovska T, Synold TW, Palmer J, Thompson R, Li L, Hoang DH, Zhang B, Ghoda L, Kowolik C, ... ... Gandhi V, et al. 8-chloro-adenosine activity in FLT3-ITD acute myeloid leukemia. Journal of Cellular Physiology. PMID 30770553 DOI: 10.1002/Jcp.28294 |
0.463 |
|
| 2019 |
Vangapandu HV, Gandhi V. Extracellular Flux Assays to Determine Oxidative Phosphorylation and Glycolysis in Chronic Lymphocytic Leukemia Cells. Methods in Molecular Biology (Clifton, N.J.). 1881: 121-128. PMID 30350202 DOI: 10.1007/978-1-4939-8876-1_10 |
0.381 |
|
| 2019 |
Bertilaccio MTS, Zhang R, Banerjee P, Gandhi V. In Vitro Assay to Study CLL and Monocyte Interactions. Methods in Molecular Biology (Clifton, N.J.). 1881: 113-119. PMID 30350201 DOI: 10.1007/978-1-4939-8876-1_9 |
0.401 |
|
| 2019 |
Aslan B, Mahendra M, Peoples MD, Marszalek JR, Vellano CP, Zheng X, Wang J, Taverna P, Gandhi V. Abstract 317: Vecabrutinib inhibits C481 mutated Bruton's tyrosine kinase and its downstream signaling in vitro Cancer Research. 79: 317-317. DOI: 10.1158/1538-7445.Sabcs18-317 |
0.451 |
|
| 2018 |
Chen LS, Bose P, Cruz ND, Jiang Y, Wu Q, Thompson PA, Feng S, Kroll MH, Qiao W, Huang X, Jain N, Wierda WG, Keating MJ, Gandhi V. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood. PMID 30254130 DOI: 10.1182/Blood-2018-06-860593 |
0.33 |
|
| 2018 |
Elsayed AH, Cao X, Crews KR, Gandhi V, Plunkett W, Rubnitz JE, Ribeiro RC, Pounds SB, Lamba JK. Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients. Pharmacogenomics. PMID 30088438 DOI: 10.2217/Pgs-2018-0086 |
0.374 |
|
| 2018 |
Abou Dalle I, Cortes JE, Pinnamaneni P, Lamothe B, Diaz Duque A, Randhawa J, Pemmaraju N, Jabbour E, Ferrajoli A, Wierda WG, Estrov Z, Konopleva M, Ravandi F, Alvarado Y, Borthakur G, ... Gandhi V, et al. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta Haematologica. 140: 30-39. PMID 30071517 DOI: 10.1159/000490092 |
0.39 |
|
| 2018 |
Vangapandu HV, Alston B, Morse J, Ayres ML, Wierda WG, Keating MJ, Marszalek JR, Gandhi V. Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells. Oncotarget. 9: 24980-24991. PMID 29861847 DOI: 10.18632/Oncotarget.25166 |
0.461 |
|
| 2018 |
Buettner R, Nguyen LXT, Kumar B, Morales CJ, Liu C, Chen LS, Pemovska T, Thompson R, Li L, Hoang DH, Zhang B, Ghoda L, Kowolik C, Kontro M, Wennerberg K, ... ... Gandhi V, et al. Antileukemic Activity of 8-Chloro-Adenosine (8-Cl-Ado) Is Mediated By Mir-155 Degradation and ErbB3 Binding Protein (Ebp1)-Dependent p53 Activation: A Novel Therapeutic Approach for FLT3-ITD Acute Myeloid Leukemia (AML) Blood. 132: 3938-3938. DOI: 10.1182/Blood-2018-99-119880 |
0.401 |
|
| 2017 |
Patel VK, Lamothe B, Ayres ML, Gay J, Cheung J, Balakrishnan K, Ivan C, Morse J, Nelson M, Keating MJ, Wierda WG, Marszalek JR, Gandhi V. Pharmacodynamics and proteomic analysis of acalabrutinib therapy: Similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia. PMID 29099493 DOI: 10.1038/Leu.2017.321 |
0.447 |
|
| 2017 |
Vangapandu HV, Chen H, Wierda WG, Keating MJ, Korkut A, Gandhi V. Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells. Leukemia & Lymphoma. 1-12. PMID 28971726 DOI: 10.1080/10428194.2017.1376747 |
0.417 |
|
| 2017 |
Vangapandu HV, Ayres ML, Bristow CA, Wierda WG, Keating MJ, Balakrishnan K, Stellrecht CM, Gandhi V. The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells. Neoplasia (New York, N.Y.). 19: 762-771. PMID 28863345 DOI: 10.1016/J.Neo.2017.07.004 |
0.464 |
|
| 2017 |
Vangapandu H, Havranek O, Ayres M, Kaipparettu BA, Balakrishnan K, Wierda W, Keating MJ, Davis RE, Stellrecht CM, Gandhi V. B cell receptor signaling regulates metabolism in Chronic Lymphocytic Leukemia. Molecular Cancer Research : McR. PMID 28835371 DOI: 10.1158/1541-7786.Mcr-17-0026 |
0.416 |
|
| 2017 |
Stellrecht CM, Chen LS, Ayres ML, Dennison JB, Shentu S, Chen Y, Keating MJ, Wierda WG, Gandhi V. Chlorinated adenosine analogue induces AMPK and autophagy in chronic lymphocytic leukaemia cells during therapy. British Journal of Haematology. PMID 28737232 DOI: 10.1111/Bjh.14859 |
0.447 |
|
| 2017 |
Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, et al. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leukemia & Lymphoma. 1-8. PMID 28718728 DOI: 10.1080/10428194.2017.1349907 |
0.356 |
|
| 2017 |
Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, et al. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. PMID 28708931 DOI: 10.1002/Cncr.30883 |
0.339 |
|
| 2017 |
Wang Y, Fan H, Balakrishnan K, Lin Z, Cao S, Chen W, Fan Y, Guthrie QA, Sun H, Teske KA, Gandhi V, Arnold LA, Peng X. Hydrogen peroxide activated quinone methide precursors with enhanced DNA cross-linking capability and cytotoxicity towards cancer cells. European Journal of Medicinal Chemistry. 133: 197-207. PMID 28388522 DOI: 10.1016/J.Ejmech.2017.03.041 |
0.333 |
|
| 2017 |
Vangapandu HV, Jain N, Gandhi V. Duvelisib: A Phosphoinositide-3 Kinase δ/γ Inhibitor for Chronic Lymphocytic Leukemia. Expert Opinion On Investigational Drugs. PMID 28388280 DOI: 10.1080/13543784.2017.1312338 |
0.469 |
|
| 2017 |
Baljevic M, Zaman S, Baladandayuthapani V, Lin YH, de Partovi CM, Berkova Z, Amini B, Thomas SK, Shah JJ, Weber DM, Fu M, Cleeland CS, Wang XS, Stellrecht CM, Davis RE, ... Gandhi V, et al. Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. Annals of Hematology. PMID 28337527 DOI: 10.1007/S00277-017-2980-3 |
0.407 |
|
| 2017 |
Modi P, Balakrishnan K, Yang Q, Wierda WG, Keating MJ, Gandhi V. Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells. Oncotarget. PMID 28187444 DOI: 10.18632/Oncotarget.15180 |
0.438 |
|
| 2017 |
Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Leukemia & Lymphoma. 1-17. PMID 28140720 DOI: 10.1080/10428194.2017.1283032 |
0.362 |
|
| 2017 |
Jain N, Thompson PA, Burger JA, Borthakur G, Bose P, Estrov Z, Ferrajoli A, Gandhi V, Plunkett W, Lopez W, Kantarjian HM, O'Brien SM, Keating MJ, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (GA101) (iFCG) for previously untreated patients with chronic lymphocytic leukemia (CLL) with mutated IGHV and non-del (17p). Journal of Clinical Oncology. 35: 7522-7522. DOI: 10.1200/Jco.2017.35.15_Suppl.7522 |
0.309 |
|
| 2017 |
Issa GC, Kantarjian HM, Short NJ, Ravandi F, Huang X, Garcia-Manero G, Plunkett W, Gandhi V, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, et al. Idarubicin and cytarabine with clofarabine or fludarabine in adults with newly diagnosed acute myeloid leukemia: Updated results of a randomized phase II study. Journal of Clinical Oncology. 35: 7037-7037. DOI: 10.1200/Jco.2017.35.15_Suppl.7037 |
0.318 |
|
| 2017 |
Vangapandu HV, Havranek O, Wierda WG, Keating MJ, Davis RE, Stellrecht CM, Gandhi V. Abstract 3547: B cell receptor signaling regulates cellular metabolism in Chronic Lymphocytic Leukemia Cancer Research. 77: 3547-3547. DOI: 10.1158/1538-7445.Am2017-3547 |
0.45 |
|
| 2016 |
Patel V, Balakrishnan K, Bibikova E, Ayres M, Keating MJ, Wierda W, Gandhi V. Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28034907 DOI: 10.1158/1078-0432.Ccr-16-1446 |
0.454 |
|
| 2016 |
Patel VM, Balakrishnan K, Douglas M, Tibbitts T, Xu EY, Kutok JL, Ayers M, Sarkar A, Guerrieri R, Wierda WG, O'Brien S, Jain N, Stern HM, Gandhi V. Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199). Leukemia. PMID 28017967 DOI: 10.1038/Leu.2016.382 |
0.488 |
|
| 2016 |
Kadia TM, Gandhi V. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma. Expert Review of Hematology. PMID 27869523 DOI: 10.1080/17474086.2017.1262757 |
0.389 |
|
| 2016 |
Mendes VI, Bartholomeusz GA, Ayres M, Gandhi V, Salvador JA. Corrigendum to "Synthesis and cytotoxic activity of novel A-ring cleaved ursolic acid derivatives in human non-small cell lung cancer cells" [Eur. J. Med. Chem. 123 (2016) 317-331]. European Journal of Medicinal Chemistry. 124: 1004-1005. PMID 27783971 DOI: 10.1016/J.Ejmech.2016.09.088 |
0.331 |
|
| 2016 |
Phillip CJ, Zaman S, Shentu S, Balakrishnan K, Zhang J, Baladandayuthapani V, Taverna P, Redkar S, Wang M, Stellrecht CM, Gandhi V. Erratum to: Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. Journal of Hematology & Oncology. 9: 110. PMID 27737688 DOI: 10.1186/s13045-016-0335-5 |
0.747 |
|
| 2016 |
Jain N, Balakrishnan K, Ferrajoli A, O'Brien SM, Burger JA, Kadia TM, Cortes JE, Ayres ML, Tambaro FP, Keating MJ, Gandhi V, Wierda WG. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. Oncotarget. PMID 27655665 DOI: 10.18632/Oncotarget.12054 |
0.368 |
|
| 2016 |
Mendes VI, Bartholomeusz GA, Ayres M, Gandhi V, Salvador JA. Synthesis and cytotoxic activity of novel A-ring cleaved ursolic acid derivatives in human non-small cell lung cancer cells. European Journal of Medicinal Chemistry. 123: 317-331. PMID 27484517 DOI: 10.1016/J.Ejmech.2016.07.045 |
0.375 |
|
| 2016 |
Yang Q, Chen LS, Ha MJ, Do KA, Neelapu SS, Gandhi V. Idelalisib impacts cell growth through inhibiting translation regulatory mechanisms in mantle cell lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27342398 DOI: 10.1158/1078-0432.Ccr-15-3135 |
0.464 |
|
| 2016 |
Balakrishnan K, Fu M, Onida F, Wierda WG, Keating MJ, Gandhi V. Reactivation of smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of smac mimetic. Oncotarget. PMID 27223062 DOI: 10.18632/Oncotarget.8462 |
0.385 |
|
| 2016 |
Chen LS, Yang JY, Liang H, Cortes JE, Gandhi V. Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia. Leukemia & Lymphoma. 1-11. PMID 27054578 DOI: 10.3109/10428194.2016.1166489 |
0.481 |
|
| 2016 |
Lamothe B, Wierda W, Keating MJ, Gandhi V. Carfilzomib triggers cell death in chronic lymphocytic leukemia by inducing proapoptotic and endoplasmic reticulum stress responses. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27026200 DOI: 10.1158/1078-0432.Ccr-15-2522 |
0.415 |
|
| 2016 |
Buettner R, Chen C, Kumar B, Morales C, Chen LS, Wennerberg K, Thompson R, Pemovska T, Li L, Zhang B, Kowolik C, Kontro M, Leitch C, Horne D, Palmer J, ... Gandhi V, et al. 8-Chloro-Adenosine Inhibits Molecular Poor-Risk Acute Myeloid Leukemia (AML) and Leukemic Stem Cells (LSC) Growth and Synergizes with the BCL-2 Inhibitor Venetoclax (ABT-199) Blood. 128: 2758-2758. DOI: 10.1182/Blood.V128.22.2758.2758 |
0.482 |
|
| 2015 |
Sarkar A, Balakrishnan K, Chen J, Patel V, Neelapu SS, McMurray JS, Gandhi V. Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma. Oncotarget. PMID 26658105 DOI: 10.18632/Oncotarget.6505 |
0.389 |
|
| 2015 |
Kearney AY, Fan YH, Giri U, Saigal B, Gandhi V, Heymach JV, Zurita AJ. 8-Chloroadenosine Sensitivity in Renal Cell Carcinoma Is Associated with AMPK Activation and mTOR Pathway Inhibition. Plos One. 10: e0135962. PMID 26313261 DOI: 10.1371/Journal.Pone.0135962 |
0.442 |
|
| 2015 |
Zaman S, Wang R, Gandhi V. Targeting executioner procaspase-3 with the procaspase-activating compound B-PAC-1 induces apoptosis in multiple myeloma cells. Experimental Hematology. 43: 951-962.e3. PMID 26257207 DOI: 10.1016/J.Exphem.2015.07.005 |
0.465 |
|
| 2015 |
Wang J, Yin H, Panandikar A, Gandhi V, Sen S. Elevated cyclin A associated kinase activity promotes sensitivity of metastatic human cancer cells to DNA antimetabolite drug. International Journal of Oncology. PMID 26058363 DOI: 10.3892/ijo.2015.3037 |
0.322 |
|
| 2015 |
Balakrishnan K, Peluso M, Fu M, Rosin NY, Burger JA, Wierda WG, Keating MJ, Faia K, O'Brien S, Kutok JL, Gandhi V. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. Leukemia. PMID 25917267 DOI: 10.1038/leu.2015.105 |
0.375 |
|
| 2015 |
Cervantes-Gomez F, Lamothe B, Woyach JA, Wierda WG, Keating MJ, Balakrishnan K, Gandhi V. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 25829398 DOI: 10.1158/1078-0432.CCR-14-2809 |
0.352 |
|
| 2015 |
Zaman S, Shentu S, Yang J, He J, Orlowski RZ, Stellrecht CM, Gandhi V. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells. Neoplasia (New York, N.Y.). 17: 289-300. PMID 25810013 DOI: 10.1016/J.Neo.2015.01.006 |
0.508 |
|
| 2015 |
Yang Q, Modi P, Newcomb T, Quéva C, Gandhi V. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1537-42. PMID 25670221 DOI: 10.1158/1078-0432.Ccr-14-2034 |
0.472 |
|
| 2015 |
Patel V, Balakrishnan K, Keating MJ, Wierda WG, Gandhi V. Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells. Blood. 125: 1126-36. PMID 25538042 DOI: 10.1182/blood-2014-01-546796 |
0.326 |
|
| 2015 |
Yang Q, Modi P, Ramanathan S, Quéva C, Gandhi V. Idelalisib for the treatment of B-cell malignancies Expert Opinion On Orphan Drugs. 3: 109-123. DOI: 10.1517/21678707.2014.978858 |
0.453 |
|
| 2015 |
Buettner R, Chen C, Kumar B, Chen LS, Wennerberg K, Thompson R, Pemovska T, Li L, Gandhi V, Marcucci G, Pullarkat V, Rosen ST. 8-Chloro-Adenosine Inhibits Molecular Poor-Risk Acute Myeloid Leukemia (AML) and Leukemic Stem Cells (LSC) Growth Via Novel RNA- and ATP-Directed Mechanisms: A Novel Therapeutic Approach for AML Blood. 126: 792-792. DOI: 10.1182/Blood.V126.23.792.792 |
0.436 |
|
| 2015 |
Stellrecht CM, Chen LS, Ayres ML, Heymach JV, Gandhi V. Abstract 673: Vulnerability of LKB1 deficient NSCLC to C8-modified adenosine analogs is associated with diminished autophagy induction Cancer Research. 75: 673-673. DOI: 10.1158/1538-7445.Am2015-673 |
0.469 |
|
| 2015 |
Yang Q, Chen LS, Neelapu SS, Gandhi V. Abstract 2663: Idelalisib impacts cell growth through inhibiting translation regulatory mechanisms in mantle cell lymphoma Cancer Research. 75: 2663-2663. DOI: 10.1158/1538-7445.Am2015-2663 |
0.505 |
|
| 2015 |
Vangapandu HV, Balakrishnan K, Ayres ML, Wierda WG, Keating MJ, Stellrecht CM, Gandhi V. Abstract 2658: Stromal microenvironment modulates mitochondrial metabolism in chronic lymphocytic leukemia cells and is abrogated by PI3K δ and γ inhibition Cancer Research. 75: 2658-2658. DOI: 10.1158/1538-7445.Am2015-2658 |
0.483 |
|
| 2015 |
Patel VM, Balakrishnan K, Guerrieri R, Wierda W, O'Brien S, Gandhi V. Abstract 2657: Elevated level of BCL-2 is the primary target for inhibition during duvelisib (IPI-145) therapy: ABT-199 neutralizes the resistance mechanism in chronic lymphocytic leukemia Cancer Research. 75: 2657-2657. DOI: 10.1158/1538-7445.Am2015-2657 |
0.451 |
|
| 2014 |
Balakrishnan K, Burger JA, Fu M, Doifode T, Wierda WG, Gandhi V. Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia. Neoplasia (New York, N.Y.). 16: 1036-46. PMID 25499217 DOI: 10.1016/J.Neo.2014.10.002 |
0.457 |
|
| 2014 |
Yang Q, Chen LS, Gandhi V. Mechanism-based combinations with Pim kinase inhibitors in cancer treatments. Current Pharmaceutical Design. 20: 6670-81. PMID 25341939 |
0.317 |
|
| 2014 |
El-Mabhouh AA, Ayres ML, Shpall EJ, Baladandayuthapani V, Keating MJ, Wierda WG, Gandhi V. Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells. Blood. 123: 3780-9. PMID 24747434 DOI: 10.1182/Blood-2013-12-541433 |
0.462 |
|
| 2014 |
Gandhi V, Plunkett W, Cortes JE. Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1735-40. PMID 24501394 DOI: 10.1158/1078-0432.Ccr-13-1283 |
0.412 |
|
| 2014 |
Faderl S, Balakrishnan K, Thomas DA, Ravandi F, Borthakur G, Burger J, Ferrajoli A, Cortes J, O'Brien S, Kadia T, Feliu J, Plunkett W, Gandhi V, Kantarjian HM. Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia. Clinical Lymphoma, Myeloma & Leukemia. 14: 231-8. PMID 24440659 DOI: 10.1016/J.Clml.2013.12.001 |
0.326 |
|
| 2014 |
Zaman S, Wang R, Gandhi V. Targeting the apoptosis pathway in hematologic malignancies. Leukemia & Lymphoma. 55: 1980-92. PMID 24295132 DOI: 10.3109/10428194.2013.855307 |
0.378 |
|
| 2014 |
Duque AD, Randhawa J, Kantarjian HM, Pemmaraju N, Jabbour E, Ferrajoli A, Wierda WG, Estrov Z, Konopleva M, Ravandi F, Alvarado Y, Gandhi V, Borthakur G, Cortes JE. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Refractory / Relapsed AML Blood. 124: 3731-3731. DOI: 10.1182/Blood.V124.21.3731.3731 |
0.376 |
|
| 2014 |
Yang C, Cortez MA, Giri U, Gudikote J, Wierda WG, Gandhi V, Byers LA, Heymach JV. Abstract 5480: NSCLC cells with LKB1 mutation are vulnerable to energetic and oxidative stresses induced by 8-Chloroadenosine Cancer Research. 74: 5480-5480. DOI: 10.1158/1538-7445.Am2014-5480 |
0.421 |
|
| 2014 |
Cervantes-Gomez F, Balakrishnan K, Wierda WG, Keating MJ, Gandhi V. Abstract 4769:Ex-vivoandin-vitrocombination strategies with ibrutinib in chronic lymphocytic leukemia Cancer Research. 74: 4769-4769. DOI: 10.1158/1538-7445.Am2014-4769 |
0.487 |
|
| 2014 |
Shah P, Balakrishnan K, Wierda W, Gandhi V. Abstract 4530: Mechanism-based combination therapy of PI3 kinase delta-specific inhibitor Idelalisib with Bendamustine in chronic lymphocytic leukemia Cancer Research. 74: 4530-4530. DOI: 10.1158/1538-7445.Am2014-4530 |
0.492 |
|
| 2014 |
Yang Q, Chen LS, Neelapu SS, Gandhi V. Abstract 4529: The PI3Kδ inhibitor, idelalisib, inhibits transcription and translation through PI3K/Akt pathway in mantle cell lymphoma Cancer Research. 74: 4529-4529. DOI: 10.1158/1538-7445.Am2014-4529 |
0.499 |
|
| 2014 |
Vangapandu HV, Balakrishnan K, Wierda WG, Keating MJ, Stellrecht CM, Gandhi V. Abstract 4328: Marrow stromal cells promote mitochondrial energy metabolism in primary CLL cells without impacting cellular proliferation Cancer Research. 74: 4328-4328. DOI: 10.1158/1538-7445.Am2014-4328 |
0.454 |
|
| 2014 |
Sarkar AK, Balakrishnan K, Ayres M, Neelapu SS, Gandhi V. Abstract 313: Essential role of ataxia telangiectasia in mitochondrial autophagy in mantle cell lymphoma Cancer Research. 74: 313-313. DOI: 10.1158/1538-7445.Am2014-313 |
0.395 |
|
| 2014 |
Zaman S, Stellrecht CM, Orlowski RZ, Gandhi V. Abstract 1710: Bortezomib and lenalidomide resistant myeloma cells overexpress the hepatocyte growth factor/MET signaling axis and respond to MET kinase inhibitors Cancer Research. 74: 1710-1710. DOI: 10.1158/1538-7445.Am2014-1710 |
0.467 |
|
| 2013 |
Phillip CJ, Zaman S, Shentu S, Balakrishnan K, Zhang J, Baladandayuthapani V, Taverna P, Redkar S, Wang M, Stellrecht CM, Gandhi V. Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. Journal of Hematology & Oncology. 6: 92. PMID 24326130 DOI: 10.1186/1756-8722-6-92 |
0.769 |
|
| 2013 |
Yang Q, Chen LS, Neelapu SS, Gandhi V. Combination of Pim kinase inhibitor SGI-1776 and bendamustine in B-cell lymphoma. Clinical Lymphoma, Myeloma & Leukemia. 13: S355-62. PMID 24290221 DOI: 10.1016/j.clml.2013.05.024 |
0.364 |
|
| 2013 |
Cao X, Mitra AK, Pounds S, Crews KR, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi S, Campana D, Downing J, Rubnitz JE, Ribeiro RC, Lamba JK. RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. Pharmacogenomics. 14: 1449-66. PMID 24024897 DOI: 10.2217/Pgs.13.131 |
0.378 |
|
| 2013 |
Cervantes-Gomez F, Chen LS, Orlowski RZ, Gandhi V. Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma. Clinical Lymphoma, Myeloma & Leukemia. 13: S317-29. PMID 23988451 DOI: 10.1016/J.Clml.2013.05.019 |
0.437 |
|
| 2013 |
Balakrishnan K, Gandhi V. Bcl-2 antagonists: a proof of concept for CLL therapy. Investigational New Drugs. 31: 1384-94. PMID 23907405 DOI: 10.1007/S10637-013-0002-4 |
0.401 |
|
| 2013 |
Balakrishnan K, Ravandi F, Bantia S, Franklin A, Gandhi V. Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia. Clinical Lymphoma, Myeloma & Leukemia. 13: 458-66. PMID 23773454 DOI: 10.1016/J.Clml.2013.04.009 |
0.393 |
|
| 2013 |
Balakrishnan K, Aggarwal S, Wierda W, Gandhi V. Bax and Bak are required for apogossypolone, a BH3-mimetic, induced apoptosis in chronic lymphocytic leukemia cells. Leukemia & Lymphoma. 54: 1097-100. PMID 22866921 DOI: 10.3109/10428194.2012.718344 |
0.446 |
|
| 2013 |
Pierce DW, Ponader S, Balakrishnan K, Gandhi V, Wierda WG, O'Brien S, Heise C, Nacht M, Aslanian S, Liu X, Hong S, Wu S, Zavodovskaya M, Marine J, Barnett E, et al. Target Engagement, Pathway Inhibition, and Efficacy Of The Bruton’s Tyrosine Kinase (Btk) Inhibitor CC-292 Blood. 122: 4169-4169. DOI: 10.1182/Blood.V122.21.4169.4169 |
0.422 |
|
| 2013 |
Peluso M, Fu M, Rosin NY, Burger JA, Wierda WG, Keating MJ, Faia K, O'Brien S, Kutok J, McGovern K, Gandhi V. Inhibition Of PI3K-δ and -γ Isoforms By IPI-145 In Chronic Lymphocytic Leukemia Overcomes Signals From PI3K/AKT/S6 Pathway and Promotes Apoptosis Blood. 122: 4167-4167. DOI: 10.1182/Blood.V122.21.4167.4167 |
0.497 |
|
| 2013 |
Orlowski RZ, Zaman S, Thomas SK, Alexanian R, Shah JJ, Weber DM, Wang M, Holloway AN, Baladandayuthapani V, Lin HY, Fu M, Stellrecht CM, de Partovi CM, Gandhi V. Phase II Study Of The c-MET Inhibitor ARQ 197 (Tivantinib) In Patients With Relapsed Or Relapsed/Refractory Multiple Myeloma (RRMM) Blood. 122: 1953-1953. DOI: 10.1182/Blood.V122.21.1953.1953 |
0.417 |
|
| 2013 |
Stellrecht CM, Shentu S, Ayres ML, Gandhi V. Abstract 5506:In vivoactivity of the ribonucleoside analogue 8-chloro-adenosine in breast cancer mouse models. Cancer Research. 73: 5506-5506. DOI: 10.1158/1538-7445.Am2013-5506 |
0.348 |
|
| 2013 |
Sarker A, Chen J, Neelapu SS, Balakrishnan K, Gandhi V. Abstract 3347: L14R8, a Pac derivative, induces casapase-3 mediated apoptosis in mantle cell lymphoma. Cancer Research. 73: 3347-3347. DOI: 10.1158/1538-7445.Am2013-3347 |
0.473 |
|
| 2013 |
Patel VM, Balakrishnan K, Wierda W, Gandhi V. Abstract 3338: Novel caspase-3 activator, L14R8, induces apoptosis in chronic lymphocytic leukemia cells. Cancer Research. 73: 3338-3338. DOI: 10.1158/1538-7445.Am2013-3338 |
0.438 |
|
| 2013 |
Zaman S, Wang R, Gandhi V. Abstract 3328: Caspase activation as an approach to treat multiple myeloma. Cancer Research. 73: 3328-3328. DOI: 10.1158/1538-7445.Am2013-3328 |
0.468 |
|
| 2013 |
Balakrishnan K, Fu M, Onida F, Wierda WG, Keating M, Gandhi V. Abstract 3325: Role of smac-mimetic in restoring apoptosis in chronic lymphocytic leukemia . Cancer Research. 73: 3325-3325. DOI: 10.1158/1538-7445.Am2013-3325 |
0.407 |
|
| 2013 |
Yang Q, Chen LS, Neelapu SS, Lanutti BJ, Gandhi V. Abstract 3265: PI3Kδ inhibitor, GS-1101, impacts transcription and translation in mantle cell lymphoma. Cancer Research. 73: 3265-3265. DOI: 10.1158/1538-7445.Am2013-3265 |
0.51 |
|
| 2013 |
Gomez F, Chen L, Wierda W, Gandhi V. Abstract 2057: In vitro effect of AZD1208 (Pim Kinase Inhibitor) and 17-AAG (HSP90 Inhibitor) combination in CLL. Cancer Research. 73: 2057-2057. DOI: 10.1158/1538-7445.Am2013-2057 |
0.478 |
|
| 2013 |
Chen LS, Cortes JE, Gandhi V. Abstract 1050: Mechanisms of action of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia cells. Cancer Research. 73: 1050-1050. DOI: 10.1158/1538-7445.Am2013-1050 |
0.483 |
|
| 2013 |
Zaman S, Stellrecht CM, Shentu S, Bjorklund CC, Orlowski RZ, Gandhi V. Targeting the Pro-Survival Protein c-MET With ARQ 197 Inhibits Growth of Multiple Myeloma Cells Clinical Lymphoma, Myeloma & Leukemia. 13. DOI: 10.1016/J.Clml.2013.07.092 |
0.384 |
|
| 2013 |
Patel V, Balakrishnan K, Wierda WG, Gandhi V. Novel Caspase-3 Activator, L14R8, Induces Apoptosis in CLL cells Clinical Lymphoma, Myeloma & Leukemia. 13. DOI: 10.1016/J.Clml.2013.07.061 |
0.372 |
|
| 2013 |
Cervantes-Gomez F, Wierda WG, Gandhi V. In vitro Effect of AZD1208 (Pim Kinase Inhibitor) and 17-AAG (HSP90 Inhibitor) Combination in CLL Clinical Lymphoma, Myeloma & Leukemia. 13. DOI: 10.1016/J.Clml.2013.07.060 |
0.351 |
|
| 2012 |
Yang Q, Chen LS, Neelapu SS, Miranda RN, Medeiros LJ, Gandhi V. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma. Blood. 120: 3491-500. PMID 22955922 DOI: 10.1182/blood-2012-02-412643 |
0.385 |
|
| 2012 |
McBrayer SK, Yarrington M, Qian J, Feng G, Shanmugam M, Gandhi V, Krett NL, Rosen ST. Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasms. Plos One. 7: e41455. PMID 22848499 DOI: 10.1371/journal.pone.0041455 |
0.349 |
|
| 2012 |
Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clinical Lymphoma, Myeloma & Leukemia. 12: 244-51. PMID 22534616 DOI: 10.1016/J.Clml.2012.03.003 |
0.348 |
|
| 2012 |
Pillai RN, Chen LS, Ayres ML, Nowak BJ, Thomas MW, Shpall EJ, Keating MJ, Gandhi V. Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells. Leukemia & Lymphoma. 53: 2024-32. PMID 22448923 DOI: 10.3109/10428194.2012.678003 |
0.457 |
|
| 2012 |
Balakrishnan K, Gandhi V. Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia. Expert Opinion On Investigational Drugs. 21: 409-23. PMID 22409342 DOI: 10.1517/13543784.2012.668526 |
0.4 |
|
| 2012 |
Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O'Brien S, Chiorazzi N, Burger JA. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 119: 1182-9. PMID 22180443 DOI: 10.1182/Blood-2011-10-386417 |
0.494 |
|
| 2012 |
Borthakur G, Cortes JE, O'Brien SM, Kadia TM, Estrov Z, Faderl S, Ravandi F, Gandhi V, Plunkett W, Bass J, Brandt M, Kantarjian H. Effect of fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on relapse-free survival in patients with newly diagnosed core-binding factor acute myelogenous leukemia. Journal of Clinical Oncology. 30: 6528-6528. DOI: 10.1200/Jco.2012.30.15_Suppl.6528 |
0.365 |
|
| 2012 |
Dorkhom SJ, Zaman S, Thomas SK, Alexanian R, Shah JJ, Weber DM, Wang M, Anderson ML, Baladandayuthapani V, Lin YH, Fu M, Stellrecht CM, de Partovi CM, Gandhi VV, Orlowski RZ. Phase II Study of the c-Met Inhibitor ARQ 197 (Tivantinib) in Patients with Relapsed Multiple Myeloma. Blood. 120: 2976-2976. DOI: 10.1182/Blood.V120.21.2976.2976 |
0.345 |
|
| 2012 |
Zaman S, Stellrecht CM, Shentu S, Kuhn DJ, Bjorklund CC, Orlowski RZ, Gandhi V. Abstract 844: Targeting the pro-survival protein c-MET with ARQ 197 inhibits growth of multiple myeloma cells Cancer Research. 72: 844-844. DOI: 10.1158/1538-7445.Am2012-844 |
0.477 |
|
| 2012 |
Balakrishnan K, Ayres M, Onida F, Wierda W, Keating M, Gandhi V. Abstract 4674: Restoration of Smac-mediated apoptosis in chronic lymphocytic leukemia Cancer Research. 72: 4674-4674. DOI: 10.1158/1538-7445.Am2012-4674 |
0.441 |
|
| 2012 |
Stellrecht CM, Dennison JB, Schiff R, Shentu S, Gandhi V. Abstract 3926: Abrogating tamoxifen resistance with the ribonucleoside analog, 8-amino adenosine Cancer Research. 72: 3926-3926. DOI: 10.1158/1538-7445.Am2012-3926 |
0.411 |
|
| 2012 |
Patel VM, Chen LS, Wierda WG, Balakrishnan K, Gandhi V. Abstract 1490: Impact of bone marrow microenvironment on mRNA expression of genes in the apoptotic pathway in CLL cells Cancer Research. 72: 1490-1490. DOI: 10.1158/1538-7445.Am2012-1490 |
0.415 |
|
| 2011 |
Cervantes-Gomez F, Nimmanapalli R, Gandhi V. ATP analog enhances the actions of a heat shock protein 90 inhibitor in multiple myeloma cells. The Journal of Pharmacology and Experimental Therapeutics. 339: 545-54. PMID 21821695 DOI: 10.1124/Jpet.111.184903 |
0.359 |
|
| 2011 |
Chen LS, Redkar S, Taverna P, Cortes JE, Gandhi V. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood. 118: 693-702. PMID 21628411 DOI: 10.1182/Blood-2010-12-323022 |
0.499 |
|
| 2011 |
Kadia T, Gandhi V, Thomas DA, Ravandi F, Plunkett W, Ayres ML, Chen Y, Zacharian G, Borthakur G, Kantarjian HM, Keating MJ. Phase I Study of Continuous-Infusion Nelarabine in Patients with Advanced Lymphoid Malignancies Blood. 118: 4239-4239. DOI: 10.1182/Blood.V118.21.4239.4239 |
0.369 |
|
| 2011 |
Wierda WG, Balakrishnan K, Ferrajoli A, Kadia T, Cortes JE, O'Brien S, Burger JA, Tambaro FP, Jalayer A, Lerner S, Keating MJ, Gandhi V. A Phase I/II Trial of Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy for Previously Treated Patients with CLL, Blood. 118: 3901-3901. DOI: 10.1182/Blood.V118.21.3901.3901 |
0.382 |
|
| 2011 |
Daver N, Kantarjian HM, Garcia-Manero G, Cortes JE, Ravandi F, Plunkett W, Gandhi V, Faderl S, o'Brien S, Borthakur G, Kadia T, Burger JA, Konopleva M, Brandt M, Huang X, et al. Twice Daily Fludarabine and Cytarabine Combination Is Effective in Patients with Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndromes, and Blast Phase Chronic Myeloid Leukemia, Blood. 118: 3629-3629. DOI: 10.1182/Blood.V118.21.3629.3629 |
0.35 |
|
| 2011 |
Yang Q, Taverna P, Medeiros J, Neelapu SS, Chen LS, Gandhi V. Abstract 586: Targeting Pim kinases by SGI-1776 in mantle cell lymphoma Cancer Research. 71: 586-586. DOI: 10.1158/1538-7445.Am2011-586 |
0.506 |
|
| 2011 |
Patel V, Chen LS, Wierda WG, Balakrishnan K, Gandhi V. Abstract 516: Marrow stromal cell rendered stability to chronic lymphocytic leukemia cells is partly mediated by Pim kinase Cancer Research. 71: 516-516. DOI: 10.1158/1538-7445.Am2011-516 |
0.5 |
|
| 2011 |
Stellrecht CM, Balakrishnan K, Dennison JB, Shentu S, Ayres M, Wierda WG, Gandhi V. Abstract 3781: The ribonucleoside analog, 8-chloro-adenosine, induces autophagy in primary chronic lymphocytic leukemia cells in vitro and in vivo Cancer Research. 71: 3781-3781. DOI: 10.1158/1538-7445.Am2011-3781 |
0.486 |
|
| 2011 |
Patel V, Chen LS, Wierda WG, Balakrishnan K, Gandhi V. 1.25 Impact of Bone Marrow Microenvironment on 93 Apoptotic Pathway Target mRNA Expression in CLL Cells Clinical Lymphoma, Myeloma & Leukemia. 11. DOI: 10.1016/J.Clml.2011.09.026 |
0.402 |
|
| 2010 |
Dennison JB, Shanmugam M, Ayres ML, Qian J, Krett NL, Medeiros LJ, Neelapu SS, Rosen ST, Gandhi V. 8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma. Blood. 116: 5622-30. PMID 20844237 DOI: 10.1182/blood-2010-05-285866 |
0.346 |
|
| 2010 |
Al-Kali A, Gandhi V, Ayoubi M, Keating M, Ravandi F. Forodesine: review of preclinical and clinical data. Future Oncology (London, England). 6: 1211-7. PMID 20799866 DOI: 10.2217/Fon.10.83 |
0.405 |
|
| 2010 |
Chen R, Chubb S, Cheng T, Hawtin RE, Gandhi V, Plunkett W. Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line. Cancer Research. 70: 6587-97. PMID 20663900 DOI: 10.1158/0008-5472.CAN-09-3578 |
0.393 |
|
| 2010 |
Lyu MA, Rai D, Ahn KS, Sung B, Cheung LH, Marks JW, Aggarwal BB, Aguiar RC, Gandhi V, Rosenblum MG. The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo. Neoplasia (New York, N.Y.). 12: 366-75. PMID 20454508 DOI: 10.1593/Neo.91960 |
0.402 |
|
| 2010 |
Balakrishnan K, Burger JA, Quiroga MP, Henneberg M, Ayres ML, Wierda WG, Gandhi V. Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood. 116: 1083-91. PMID 20442367 DOI: 10.1182/Blood-2009-10-246199 |
0.487 |
|
| 2010 |
Balakrishnan K, Verma D, O'Brien S, Kilpatrick JM, Chen Y, Tyler BF, Bickel S, Bantia S, Keating MJ, Kantarjian H, Gandhi V, Ravandi F. Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood. 116: 886-92. PMID 20427701 DOI: 10.1182/Blood-2010-02-272039 |
0.393 |
|
| 2010 |
Dennison JB, Ayres ML, Kaluarachchi K, Plunkett W, Gandhi V. Intracellular succinylation of 8-chloroadenosine and its effect on fumarate levels. The Journal of Biological Chemistry. 285: 8022-30. PMID 20064937 DOI: 10.1074/Jbc.M109.085803 |
0.34 |
|
| 2010 |
Frey JA, Gandhi V. 8-Amino-adenosine inhibits multiple mechanisms of transcription. Molecular Cancer Therapeutics. 9: 236-45. PMID 20053765 DOI: 10.1158/1535-7163.Mct-09-0767 |
0.599 |
|
| 2010 |
Stellrecht CM, Ayres M, Arya R, Gandhi V. A unique RNA-directed nucleoside analog is cytotoxic to breast cancer cells and depletes cyclin E levels. Breast Cancer Research and Treatment. 121: 355-64. PMID 19641990 DOI: 10.1007/S10549-009-0481-3 |
0.374 |
|
| 2010 |
Lamba J, Mitra A, Crews K, Stanley P, Cao X, Gandhi V, Plunkett W, Rubnitz J, Ribeiro R. Pathway Based Pharmacogenomics of Cytarabine In Pediatric Acute Myeloid Leukemia Blood. 116: 294-294. DOI: 10.1182/Blood.V116.21.294.294 |
0.37 |
|
| 2010 |
Balakrishnan K, Burger J, Wierda W, Gandhi V. Abstract 3192: Marrow stromal cell enhanced survival of CLL cell is mediated through activation of cellular transcriptional machinery Cancer Research. 70: 3192-3192. DOI: 10.1158/1538-7445.Am10-3192 |
0.457 |
|
| 2010 |
Cervantes-Gomez F, Nimmanapalli R, Gandhi V. Abstract 2633: Adenosine analog enhances actions of 17-AAG Cancer Research. 70: 2633-2633. DOI: 10.1158/1538-7445.Am10-2633 |
0.384 |
|
| 2010 |
Chen LS, Redkar S, Taverna P, Cortes JE, Gandhi V. Abstract 1649: Pim kinase inhibitor, SGI-1776, induces apoptosis in acute myeloid leukemia primary cells Cancer Research. 70: 1649-1649. DOI: 10.1158/1538-7445.Am10-1649 |
0.519 |
|
| 2010 |
Stellrecht CM, Dennison JB, Shentu S, Gandhi V. Abstract 1631: The ribonucleoside analogue, 8-amino-adenosine, inhibits AKT and MAPK signaling in breast cancer cells Cancer Research. 70: 1631-1631. DOI: 10.1158/1538-7445.Am10-1631 |
0.445 |
|
| 2009 |
Faderl S, Thomas DA, Gandhi V, Huang X, Borthakur G, O'Brien S, Ravandi F, Plunkett W, Bretz JL, Kantarjian HM. Results of a phase I study of clofarabine (CLO) plus cyclophosphamide (CY) in adult patients (pts) with relapsed and/or refractory acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 7020. PMID 27961382 DOI: 10.1200/Jco.2009.27.15_Suppl.7020 |
0.315 |
|
| 2009 |
Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, Sivina M, Wierda WG, Estrov Z, Keating MJ, Shehata M, Jäger U, Gandhi V, Kay NE, Plunkett W, et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 114: 4441-50. PMID 19762485 DOI: 10.1182/Blood-2009-07-233718 |
0.411 |
|
| 2009 |
Chen LS, Redkar S, Bearss D, Wierda WG, Gandhi V. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 114: 4150-7. PMID 19734450 DOI: 10.1182/blood-2009-03-212852 |
0.394 |
|
| 2009 |
Dennison JB, Balakrishnan K, Gandhi V. Preclinical activity of 8-chloroadenosine with mantle cell lymphoma: roles of energy depletion and inhibition of DNA and RNA synthesis. British Journal of Haematology. 147: 297-307. PMID 19709085 DOI: 10.1111/j.1365-2141.2009.07850.x |
0.347 |
|
| 2009 |
Shanmugam M, McBrayer SK, Qian J, Raikoff K, Avram MJ, Singhal S, Gandhi V, Schumacker PT, Krett NL, Rosen ST. Targeting glucose consumption and autophagy in myeloma with the novel nucleoside analogue 8-aminoadenosine. The Journal of Biological Chemistry. 284: 26816-30. PMID 19648108 DOI: 10.1074/Jbc.M109.000646 |
0.367 |
|
| 2009 |
Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG, Gandhi V, Burger JA. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood. 114: 1029-37. PMID 19491390 DOI: 10.1182/Blood-2009-03-212837 |
0.444 |
|
| 2009 |
Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ, Gandhi V, Plunkett W. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 113: 4637-45. PMID 19234140 DOI: 10.1182/blood-2008-12-190256 |
0.356 |
|
| 2009 |
Sánchez-Vega B, Gandhi V. Glucocorticoid resistance in a multiple myeloma cell line is regulated by a transcription elongation block in the glucocorticoid receptor gene (NR3C1). British Journal of Haematology. 144: 856-64. PMID 19133980 DOI: 10.1111/J.1365-2141.2008.07549.X |
0.376 |
|
| 2009 |
Stellrecht CM, Gandhi V. MET receptor tyrosine kinase as a therapeutic anticancer target. Cancer Letters. 280: 1-14. PMID 19100682 DOI: 10.1016/J.Canlet.2008.10.045 |
0.38 |
|
| 2009 |
Balakrishnan K, Burger JA, Wierda WG, Gandhi V. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood. 113: 149-53. PMID 18836097 DOI: 10.1182/Blood-2008-02-138560 |
0.443 |
|
| 2009 |
Phillip CJ, Stellrecht CM, Nimmanapalli R, Gandhi V. Targeting MET transcription as a therapeutic strategy in multiple myeloma. Cancer Chemotherapy and Pharmacology. 63: 587-97. PMID 18509644 DOI: 10.1007/S00280-008-0770-2 |
0.756 |
|
| 2009 |
Lamba JK, Mitra A, Crews K, Pounds S, Cao X, Gandhi V, Plunkett W, Rubnitz J, Ribeiro RC. 5'Nucleotidase (NT5C2) Genotype Influences Leukemic Blast Concentration of Ara-CTP in Pediatric Patients with Acute Myeloid Leukemia. Blood. 114: 593-593. DOI: 10.1182/Blood.V114.22.593.593 |
0.381 |
|
| 2009 |
Verma D, Balakrishnan K, O'Brien S, Thomas DA, Ferrajoli A, Wierda WG, Verma A, Faderl S, Bickel SM, Bantia S, Kantarjian HM, Keating MJ, Gandhi V, Ravandi F. Phase II, Single Center Study of Oral Forodesine in Patients with Advanced, Fludarabine-Treated Chronic Lymphocytic Leukemia (CLL). Blood. 114: 2369-2369. DOI: 10.1182/Blood.V114.22.2369.2369 |
0.447 |
|
| 2009 |
Lamba JK, Crews K, Pounds S, Cao X, Gandhi V, Plunkett W, Baker SD, Pui C, Campana D, Downing JR, Rubnitz J, Ribeiro RC. Gene Expression Patterns Associated with Cytarabine Pharmacology and Outcome in Pediatric Acute Myeloid Leukemia. Blood. 114: 114-114. DOI: 10.1182/Blood.V114.22.114.114 |
0.356 |
|
| 2009 |
Stellrecht C, Shentu S, Gandhi V. The Ribonucleoside Analog, 8-Chloro-Adenosine, Inhibits the mTOR Pathway and Induces Autophagy. Cancer Research. 69: 6116-6116. DOI: 10.1158/0008-5472.Sabcs-09-6116 |
0.473 |
|
| 2008 |
Nimmanapalli R, Gerbino E, Dalton WS, Gandhi V, Alsina M. HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma. British Journal of Haematology. 142: 551-61. PMID 18503584 DOI: 10.1111/J.1365-2141.2008.07217.X |
0.435 |
|
| 2008 |
Chen LS, Stellrecht CM, Gandhi V. RNA-directed agent, cordycepin, induces cell death in multiple myeloma cells. British Journal of Haematology. 140: 682-391. PMID 18205859 DOI: 10.1111/J.1365-2141.2007.06955.X |
0.439 |
|
| 2008 |
Borthakur G, Faderl S, Verstovsek S, Jones D, Gandhi V, Estrov Z, O'Brien S, Ravandi F, Bass J, Brandt M, Kantarjian H. Clinical and Molecular Response in Core Binding Factor Acute Myelogenous Leukemia with Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin. Blood. 114: 2056-2056. DOI: 10.1182/Blood.V114.22.2056.2056 |
0.384 |
|
| 2007 |
Gandhi V. Questions about gemcitabine dose rate: answered or unanswered? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 5691-4. PMID 18089862 DOI: 10.1200/Jco.2007.13.6879 |
0.319 |
|
| 2007 |
Gandhi V, Balakrishnan K. Pharmacology and mechanism of action of forodesine, a T-cell targeted agent. Seminars in Oncology. 34: S8-12. PMID 18086347 DOI: 10.1053/J.Seminoncol.2007.11.003 |
0.407 |
|
| 2007 |
Stellrecht CM, Phillip CJ, Cervantes-Gomez F, Gandhi V. Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase. Cancer Research. 67: 9913-20. PMID 17942923 DOI: 10.1158/0008-5472.Can-07-0770 |
0.766 |
|
| 2007 |
Lamba JK, Crews K, Pounds S, Schuetz EG, Gresham J, Gandhi V, Plunkett W, Rubnitz J, Ribeiro R. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. The Journal of Pharmacology and Experimental Therapeutics. 323: 935-45. PMID 17855478 DOI: 10.1124/Jpet.107.128595 |
0.322 |
|
| 2007 |
Flanagan SA, Gandhi V, Meckling KA. Guanosine acts intracellularly to initiate apoptosis in NB4 cells: A role for nucleoside transport. Leukemia & Lymphoma. 48: 1816-27. PMID 17786719 DOI: 10.1080/10428190701528491 |
0.435 |
|
| 2007 |
Karp JE, Ricklis RM, Balakrishnan K, Briel J, Greer J, Gore SD, Smith BD, McDevitt MA, Carraway H, Levis MJ, Gandhi V. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood. 110: 1762-9. PMID 17562873 DOI: 10.1182/Blood-2007-03-081364 |
0.38 |
|
| 2007 |
Nimmanapalli R, Lyu MA, Du M, Keating MJ, Rosenblum MG, Gandhi V. The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells. Blood. 109: 2557-64. PMID 17119117 DOI: 10.1182/Blood-2006-08-042424 |
0.412 |
|
| 2007 |
Faderl S, Thomas DA, Gandhi V, Borthakur G, Huang X, Plunkett W, Burger J, Cortes J, O’Brien S, Ravandi F, Bretz J, Kwari M, Kantarjian HM. Phase I/II Study of Clofarabine Plus Cyclophosphamide in Adults with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL). Blood. 110: 4335-4335. DOI: 10.1182/Blood.V110.11.4335.4335 |
0.325 |
|
| 2007 |
Chen R, Wierda WG, Benaissa S, Hoch U, Hawtin RE, Fox JA, Keating MJ, Gandhi V, Plunkett W. Mechanism of Action of SNS-032, a Novel Cyclin Dependent Kinase Inhibitor, in Chronic Lymphocytic Leukemia: Comparison with Flavopiridol. Blood. 110: 3112-3112. DOI: 10.1182/Blood.V110.11.3112.3112 |
0.486 |
|
| 2007 |
Lamba J, Crews K, Pounds S, Schuetz E, Gandhi V, Plunkett W, Rubnitz J, Ribeiro R. Deoxycytidine Kinase Genotype Influences Leukemia Cell Concentration of Cytarabine 5′-Triphosphate in Pediatric AML Patients. Blood. 110: 225-225. DOI: 10.1182/Blood.V110.11.225.225 |
0.377 |
|
| 2007 |
Faderl S, Garcia-Manero G, Gandhi V, Ravandi F, Borthakur G, Thomas DA, Ferrajoli A, Estrov Z, Plunkett W, Byrd A, Kwari M, Kantarjian HM. Results of an Exploratory Study of Oral (po) and Intravenous (iv) Clofarabine in Patients with Myelodysplastic Syndrome. Blood. 110: 1455-1455. DOI: 10.1182/Blood.V110.11.1455.1455 |
0.305 |
|
| 2006 |
Sánchez-Vega B, Krett N, Rosen ST, Gandhi V. Glucocorticoid receptor transcriptional isoforms and resistance in multiple myeloma cells. Molecular Cancer Therapeutics. 5: 3062-70. PMID 17172408 DOI: 10.1158/1535-7163.Mct-06-0344 |
0.374 |
|
| 2006 |
Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Research. 66: 10959-66. PMID 17108134 DOI: 10.1158/0008-5472.Can-06-1216 |
0.457 |
|
| 2006 |
Gandhi V, Plunkett W, Bonate PL, Du M, Nowak B, Lerner S, Keating MJ. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4011-7. PMID 16818700 DOI: 10.1158/1078-0432.Ccr-05-2664 |
0.344 |
|
| 2006 |
Balakrishnan K, Nimmanapalli R, Ravandi F, Keating MJ, Gandhi V. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 108: 2392-8. PMID 16778146 DOI: 10.1182/Blood-2006-03-007468 |
0.47 |
|
| 2006 |
Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M, Gandhi V, Plunkett W. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood. 107: 2517-24. PMID 16293603 DOI: 10.1182/Blood-2005-08-3351 |
0.482 |
|
| 2006 |
Faderl S, Gandhi V, O’Brien S, Giles F, Cortes J, Plunkett W, Kantarjian HM. Clofarabine Is Active in Myelodysplastic Syndrome (MDS). Blood. 108: 2660-2660. DOI: 10.1182/Blood.V108.11.2660.2660 |
0.31 |
|
| 2005 |
Balakrishnan K, Wierda WG, Keating MJ, Gandhi V. Mechanisms of cell death of chronic lymphocytic leukemia lymphocytes by RNA-directed agent, 8-NH2-adenosine. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 6745-52. PMID 16166456 DOI: 10.1158/1078-0432.Ccr-05-0553 |
0.449 |
|
| 2005 |
Chen R, Keating MJ, Gandhi V, Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood. 106: 2513-9. PMID 15972445 DOI: 10.1182/blood-2005-04-1678 |
0.377 |
|
| 2005 |
Ghias K, Ma C, Gandhi V, Platanias LC, Krett NL, Rosen ST. 8-Amino-adenosine induces loss of phosphorylation of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2, and Akt kinase: role in induction of apoptosis in multiple myeloma. Molecular Cancer Therapeutics. 4: 569-77. PMID 15827330 DOI: 10.1158/1535-7163.Mct-04-0303 |
0.438 |
|
| 2005 |
Faderl S, Gandhi V, Keating MJ, Jeha S, Plunkett W, Kantarjian HM. The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog. Cancer. 103: 1985-95. PMID 15803490 DOI: 10.1002/Cncr.21005 |
0.381 |
|
| 2005 |
Balakrishnan K, Stellrecht CM, Genini D, Ayres M, Wierda WG, Keating MJ, Leoni LM, Gandhi V. Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP. Blood. 105: 4455-62. PMID 15718423 DOI: 10.1182/Blood-2004-05-1699 |
0.479 |
|
| 2005 |
Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Kwari M, Keating M, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 105: 940-7. PMID 15486072 DOI: 10.1182/Blood-2004-05-1933 |
0.36 |
|
| 2005 |
Balakrishnan K, Ravandi F, Keating MJ, Gandhi V. Development of Forodesine Hydrochloride (FH), an Inhibitor of Purine Nucleoside Phosphorylase, for Patients with Chronic Lymphocytic Leukemia (CLL). Blood. 106: 2119-2119. DOI: 10.1182/Blood.V106.11.2119.2119 |
0.506 |
|
| 2004 |
Faderl S, Gandhi V, Giles F, Estey E, Garcia-Manero G, O Brien S, Wierda W, Kwari M, Craig A, Kantarjian HM. Clofarabine plus cytarabine (ara-C) is an active induction regimen for newly diagnosed patients (pts) ≥ age 50 with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 6609. PMID 28016579 DOI: 10.1200/Jco.2004.22.90140.6609 |
0.384 |
|
| 2004 |
Jeha S, Gandhi V, Chan KW, McDonald L, Ramirez I, Madden R, Rytting M, Brandt M, Keating M, Plunkett W, Kantarjian H. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood. 103: 784-9. PMID 14551141 DOI: 10.1182/Blood-2003-06-2122 |
0.348 |
|
| 2004 |
Faderl S, Gandhi V, Verstovsek S, Cortes J, Ravandi-Kashani F, Beran M, Garcia-Manero G, Koller C, O’Brien S, Ferrajoli A, Estrov Z, Kwari M, Plunkett W, Kantarjian HM. Clofarabine Plus Cytarabine (ARA-C) Combination Is Active in Newly Diagnosed Patients (PTS) ≥ Age 50 with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood. 104: 875-875. DOI: 10.1182/Blood.V104.11.875.875 |
0.317 |
|
| 2004 |
Jabbour E, Verstovsek S, Gandhi V, Cortes J, Giles F, Koller C, O’Brien S, Plunkett W, Garcia-Manero G, Jackson E, Kantarjian H, Andreeff M. 2 Chlorodeoxyadenosine (2-CdA) and Cytarabine (ara-C) Combination Is Effective and Safe in Idiopathic Hypereosinophilic Syndrome (HES). Blood. 104: 4764-4764. DOI: 10.1182/Blood.V104.11.4764.4764 |
0.359 |
|
| 2004 |
Isola L, Furman RR, Gandhi V, Thomas DA, Bennett JC, Bantia S, Kilpatrick JM. Antileukemic Activity and Pharmacodynamics of Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, in Phase I/II Trials in Patients with Advanced T-Cell Malignancies. Blood. 104: 4501-4501. DOI: 10.1182/Blood.V104.11.4501.4501 |
0.407 |
|
| 2004 |
Ghias K, Ma C, Gandhi V, Krett N, Rosen ST. 8-Amino-Adenosine Induces Loss of Phosphorylation of ERK1/2, p38 MAPK, and Akt Kinase: Role in Induction of Apoptosis in Multiple Myeloma. Blood. 104: 3367-3367. DOI: 10.1182/Blood.V104.11.3367.3367 |
0.48 |
|
| 2004 |
Furman RR, Gandhi VV, Bennett JC, Bantia S, Kilpatrick JM. Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, Demonstrates Clinical Activity in Phase I/II Studies in Patients with B-Cell Acute Lymphoblastic Leukemia. Blood. 104: 2743-2743. DOI: 10.1182/blood.v104.11.2743.2743 |
0.3 |
|
| 2004 |
Faderl S, Ferrajolil A, Wierda W, Verstovsek S, Ravandi-Kashani F, Garcia-Manero G, Estey E, Thomas DA, Kornblau S, Kwari M, Gandhi V, Kantarjian HM. Phase I Study of Clofarabine Plus Idarubicin and Clofarabine Plus Idarubicin Plus Cytarabine (ARA-C) in Patients (PTS) with Relapsed and Primary Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myeloid Blast Phase of Chronic Myeloid Leukemia (CML). Blood. 104: 1809-1809. DOI: 10.1182/Blood.V104.11.1809.1809 |
0.316 |
|
| 2003 |
Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G, Giles F, Faderl S, O'Brien S, Jeha S, Davis J, Shaked Z, Craig A, Keating M, Plunkett W, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 102: 2379-86. PMID 12791647 DOI: 10.1182/Blood-2003-03-0925 |
0.353 |
|
| 2003 |
Rodriguez CO, Stellrecht CM, Gandhi V. Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood. 102: 1842-8. PMID 12750168 DOI: 10.1182/blood-2003-01-0317 |
0.305 |
|
| 2003 |
Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, O'Brien S, Ibrahim N, Khuri F, Du M, Rios MB, Jeha S, McLaughlin P, Plunkett W, Keating M. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 1167-73. PMID 12637486 DOI: 10.1200/Jco.2003.04.031 |
0.309 |
|
| 2002 |
Gandhi V, Chen W, Ayres M, Rhie JK, Madden TL, Newman RA. Plasma and cellular pharmacology of 8-chloro-adenosine in mice and rats. Cancer Chemotherapy and Pharmacology. 50: 85-94. PMID 12172971 DOI: 10.1007/S00280-002-0456-0 |
0.344 |
|
| 2002 |
Gandhi V. Metabolism and mechanisms of action of bendamustine: Rationales for combination therapies Seminars in Oncology. 29: 4-11. DOI: 10.1016/S0093-7754(02)90007-2 |
0.326 |
|
| 2001 |
Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, Plunkett W, Benjamin RS. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation Journal of Clinical Oncology. 19: 3483-3489. PMID 11481354 DOI: 10.1200/Jco.2001.19.15.3483 |
0.35 |
|
| 2000 |
Kisor DF, Plunkett W, Kurtzberg J, Mitchell B, Hodge JP, Ernst T, Keating MJ, Gandhi V. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 995-1003. PMID 10694549 DOI: 10.1200/Jco.2000.18.5.995 |
0.308 |
|
| 1999 |
Aguayo A, Cortes JE, Kantarjian HM, Beran M, Gandhi V, Plunkett W, Kurtzberg J, Keating MJ. Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature. Cancer. 85: 58-64. PMID 9921974 DOI: 10.1002/(Sici)1097-0142(19990101)85:1<58::Aid-Cncr8>3.0.Co;2-E |
0.37 |
|
| 1996 |
Loughlin S, Gandhi V, Plunkett W, Zwelling LA. The effect of 9-β-D-arabinofuranosyl-2-fluoroadenine and 1-β-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells Cancer Chemotherapy and Pharmacology. 38: 261-268. PMID 8646801 DOI: 10.1007/S002800050480 |
0.382 |
|
| 1995 |
Gandhi V, Estey E, Plunkett W. Modulation of arabinosylcytosine metabolism during leukemia therapy Advances in Experimental Medicine and Biology. 370: 119-124. PMID 7544948 DOI: 10.1007/978-1-4615-2584-4_27 |
0.34 |
|
| 1994 |
Keating MJ, O'brien S, Robertson LE, Kantarjian H, Dimopoulos M, Mclaughlin P, Cabanillas F, Gregoire V, Ying-Yang L, Gandhi V, Estey E, Plunkett W. The expanding role of fludarabine in hematologic malignancies. Leukemia & Lymphoma. 14: 11-16. PMID 7533576 DOI: 10.3109/10428199409052690 |
0.391 |
|
| 1993 |
Gandhi V, Estey E, Keating MJ, Plunkett W. Biochemical modulation of arabinosylcytosine for therapy of leukemias Leukemia and Lymphoma. 10: 109-114. PMID 8481660 DOI: 10.3109/10428199309149122 |
0.376 |
|
| 1993 |
Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 11: 116-24. PMID 8418222 DOI: 10.1200/Jco.1993.11.1.116 |
0.321 |
|
| 1993 |
Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leukemia & Lymphoma. 9: 343-350. PMID 8394169 DOI: 10.3109/10428199309148532 |
0.312 |
|
| 1993 |
Suki S, Kantarjian H, Gandhi V, Estey E, O'Brien S, Beran M, Rios MB, Plunkett W, Keating M. Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia. Cancer. 72: 2155-2160. PMID 8374873 DOI: 10.1002/1097-0142(19931001)72:7<2155::Aid-Cncr2820720715>3.0.Co;2-V |
0.391 |
|
| 1992 |
Gandhi V, Huang P, Xu YZ, Heinemann V, Plunkett W. Metabolism and action of 2',2'-difluorodeoxycytidine: self-potentiation of cytotoxicity. Advances in Experimental Medicine and Biology. 125-30. PMID 1789190 DOI: 10.1007/978-1-4899-2638-8_28 |
0.332 |
|
| 1992 |
Gandhi V, Plunkett W. Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells Cancer Chemotherapy and Pharmacology. 31: 11-17. PMID 1458554 DOI: 10.1007/Bf00695988 |
0.368 |
|
| Show low-probability matches. |